The roles of orphan nuclear receptor 4 group A1 and A2 in fibrosis.

Fibrosis diseases NR4A1 NR4A2 Orphan nuclear receptor

Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
18 Jul 2024
Historique:
received: 16 05 2024
revised: 11 07 2024
accepted: 14 07 2024
medline: 20 7 2024
pubmed: 20 7 2024
entrez: 19 7 2024
Statut: aheadofprint

Résumé

Fibrosis is not a disease but rather an outcome of the pathological tissue repair response. Many myofibroblasts are activated which lead to the excessive accumulation of extracellular matrix components such as collagen and fibronectin with fibrosis. A variety of organs, including kidney, liver, lung, heart and skin, can undergo fibrosis under the stimulation of exogenous or endogenous pathogenic factors. The orphan nuclear receptor 4 group A1 (NR4A1) and nuclear receptor 4 group A2(NR4A2)are belong to the nuclear receptor subfamily and inhibit the occurrence and development of fibrosis. NR4A1 is an inhibitory factor of TGF-β signaling transduction. Overexpression of NR4A1 in fibroblasts can reduce TGF-β induced collagen deposition and fibrosis related gene expression. Here, we summarize the current research progress on the NR4A1/2 and fibrosis, providing reference for the treatment of fibrosis.

Identifiants

pubmed: 39029235
pii: S1567-5769(24)01226-8
doi: 10.1016/j.intimp.2024.112705
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

112705

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Lanjun Gao (L)

Graduate School, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.

Hongshuang Wang (H)

Graduate School, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.

Fang Fang (F)

Graduate School, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.

Jiazhi Liu (J)

Graduate School, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.

Chenchen Zhao (C)

Graduate School, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.

Jieqi Niu (J)

Graduate School, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.

Zheng Wang (Z)

Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns Research, Shijiazhuang 050091, China; Institute of Integrative Medicine, College of Integrative Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.

Yan Zhong (Y)

Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns Research, Shijiazhuang 050091, China; Institute of Integrative Medicine, College of Integrative Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China. Electronic address: zy1987821@hebcm.edu.cn.

Xiangting Wang (X)

Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns Research, Shijiazhuang 050091, China. Electronic address: wangxiangting@hebcm.edu.cn.

Classifications MeSH